Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study

Overview of attention for article published in Journal of Hematology & Oncology, August 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 3 news outlets

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 28 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 3 news stories from 3 outlets.

Dose Escalating Ruxolitinib May Limit Drug-Related Anemia in Myelofibrosis

Medical Health News, 29 Nov 2018

Beginning ruxolitinib (Jakafi) therapy at lower doses may limit the anemia frequently seen early in treatment in patients with…

Alternative Ruxolitinib Dosing Regimen May Mitigate Anemia in Patients With Myelofibrosis

AJMC, 03 Oct 2018

A recent open-label, single-arm, phase 2 study sought to assess evaluate an alternative dosing regimen for adults myelofibrosis …

Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis

Oncology Nurse Advisor , 16 Aug 2018

August 16, 2018 Ruxolitinib can improve splenomegaly and symptoms among patients with MF, but AEs such as anemia may be a side…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.